Suven Life Sciences Limited

Clinical trials sponsored by Suven Life Sciences Limited, explained in plain language.

Suven Life Sciences Limited SUVEN NSE

An Indian biopharmaceutical company focused on CNS disorders and contract research services.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Hope for Alzheimer's agitation: new drug enters final testing Results expected Dec 2026 (estimated) 🚀 Make-or-break

Browse trials soon ready across all sponsors →

Trials to join now! 1 Not yet finished but already full! 1 Completed 3

New narcolepsy drug aims to keep patients awake and strong

Symptom relief Recruiting now

This study tests a drug called samelisant in 240 people with narcolepsy (with or without cataplexy). The goal is to see if it reduces excessive daytime sleepiness and sudden muscle weakness episodes over 12 weeks. Participants will take the drug or a placebo and report their slee…

Phase 3 • Sponsor: Suven Life Sciences Limited • Aim: Symptom relief

Last updated Sep 05, 2026 00:00 UTC

Suven Life Sciences Limited

Upcoming readouts

New narcolepsy drug aims to keep patients awake and strong